| |
MEH*
(n=15) |
SCP
(n=12) |
VV/AC
(n=2) |
Total
(n=29) |
| n |
( % ) |
n |
( % ) |
n |
( % ) |
n |
( % ) |
| Low risk HPV |
|
| 32 |
7 |
(46.7) |
1 |
( 8.3) |
2 |
(100) |
10 |
(34.5) |
| 13 |
1 |
( 6.7) |
5 |
(41.7) |
--- |
--- |
6 |
(20.7) |
| 6 |
2 |
(16.7) |
2 |
(13.3) |
--- |
--- |
4 |
(13.8) |
| 7 |
--- |
--- |
2 |
(16.7) |
--- |
--- |
2 |
( 6.9) |
| 11 |
--- |
--- |
2 |
(16.7) |
--- |
--- |
2 |
( 6.9) |
| Low and high risk HPV |
|
| 16 and 32 |
2 |
(13.4) |
--- |
--- |
--- |
--- |
2 |
( 6.8) |
| 16 and 42 |
1 |
( 6.7) |
--- |
--- |
--- |
--- |
1 |
( 3.4) |
| Undetermined HPV type |
|
| 74a |
1 |
( 6.7) |
--- |
--- |
--- |
--- |
1 |
( 3.4) |
| LVX100 |
1 |
( 6.7) |
--- |
--- |
--- |
--- |
1 |
( 3.4) |
|
| MEH: Multifocal Epithelial Hyperplasia; SCP: Squamous Cell Papilloma; VV: Verruca Vulgaris; AC: Accuminated Condyloma. aThe sample had also HPV-13. |
| Table 3: HPV types and histopathological diagnosis in 29 HPV-OL samples from HIV-infected individuals. |
